Klaria Pharma Holding AB (publ.) (FRA:6FN)
Germany · Delayed Price · Currency is EUR 0.0406
-0.0042 (-9.38%)
At close: Nov 28, 2025
FRA:6FN Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 11.11 | 2.25 | 8.45 | 5.87 | - | - | Upgrade |
Other Revenue | 0.04 | - | - | - | 6.11 | 7.22 | Upgrade |
| 11.15 | 2.25 | 8.45 | 5.87 | 6.11 | 7.22 | Upgrade | |
Revenue Growth (YoY) | 680.48% | -73.41% | 44.07% | -3.99% | -15.35% | -37.59% | Upgrade |
Gross Profit | 11.15 | 2.25 | 8.45 | 5.87 | 6.11 | 7.22 | Upgrade |
Selling, General & Admin | 15.89 | 11.43 | 15.91 | 10.16 | 9.86 | 8.29 | Upgrade |
Research & Development | 28.16 | 22.11 | 24.95 | 51.36 | 63.49 | 48.44 | Upgrade |
Other Operating Expenses | - | - | -0.21 | -0.2 | 13.74 | -0.59 | Upgrade |
Operating Expenses | 44.05 | 33.53 | 40.64 | 61.31 | 87.09 | 56.15 | Upgrade |
Operating Income | -32.9 | -31.29 | -32.18 | -55.44 | -80.97 | -48.93 | Upgrade |
Interest Expense | -16.75 | -16.39 | -3.66 | -7.83 | -3.17 | -2.56 | Upgrade |
Interest & Investment Income | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | Upgrade |
Currency Exchange Gain (Loss) | -0.04 | -0.04 | 0.02 | -0.38 | 0.06 | 0.02 | Upgrade |
Other Non Operating Income (Expenses) | -0.07 | -0.03 | -0.02 | -0.02 | 30.53 | 0.06 | Upgrade |
Pretax Income | -46.02 | -47.73 | -35.84 | -63.66 | -53.55 | -51.41 | Upgrade |
Income Tax Expense | - | 0.02 | -0.06 | 0.12 | -0.01 | 0.03 | Upgrade |
Earnings From Continuing Operations | -46.02 | -47.75 | -35.78 | -63.77 | -53.53 | -51.44 | Upgrade |
Net Income | -46.02 | -47.75 | -35.78 | -63.77 | -53.53 | -51.44 | Upgrade |
Net Income to Common | -46.02 | -47.75 | -35.78 | -63.77 | -53.53 | -51.44 | Upgrade |
Shares Outstanding (Basic) | 163 | 125 | 101 | 58 | 52 | 43 | Upgrade |
Shares Outstanding (Diluted) | 163 | 127 | 101 | 58 | 52 | 43 | Upgrade |
Shares Change (YoY) | 41.84% | 25.62% | 73.49% | 12.15% | 19.58% | 39.05% | Upgrade |
EPS (Basic) | -0.28 | -0.38 | -0.36 | -1.10 | -1.03 | -1.19 | Upgrade |
EPS (Diluted) | -0.28 | -0.38 | -0.36 | -1.10 | -1.03 | -1.19 | Upgrade |
Free Cash Flow | -30.99 | -11.91 | -9.06 | -49.77 | -24.8 | -35.33 | Upgrade |
Free Cash Flow Per Share | -0.19 | -0.09 | -0.09 | -0.86 | -0.48 | -0.81 | Upgrade |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade |
Operating Margin | -295.00% | -1391.68% | -380.70% | -944.79% | -1324.82% | -677.67% | Upgrade |
Profit Margin | -412.66% | -2124.11% | -423.28% | -1086.81% | -875.88% | -712.45% | Upgrade |
Free Cash Flow Margin | -277.86% | -529.67% | -107.14% | -848.18% | -405.71% | -489.32% | Upgrade |
EBITDA | -15 | -20.07 | -21.15 | -45.09 | -70.61 | -36.07 | Upgrade |
EBITDA Margin | -134.49% | - | -250.14% | - | - | - | Upgrade |
D&A For EBITDA | 17.9 | 11.22 | 11.04 | 10.35 | 10.37 | 12.86 | Upgrade |
EBIT | -32.9 | -31.29 | -32.18 | -55.44 | -80.97 | -48.93 | Upgrade |
EBIT Margin | -295.00% | - | - | - | - | - | Upgrade |
Revenue as Reported | 8.86 | - | - | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.